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Theoretical scenario 
An orthodontist participates in an international orthodontic conference and hears from the company 
representatives of a new experimental custom-made appliance for fixed appliance treatment. According to 
its manufacturer, using this experimental appliance would bring multiple benefits including less discomfort, 
better oral hygiene, and reduced treatment duration compared to conventional appliances. 
Intrigued by these extraordinary claims, the orthodontist builds a multicentre research team and 
secures a grant from the local orthodontic scientific society to perform a large clinical trial that might provide 
definite evidence to support or reject these claims. A randomized clinical trial is set up with two parallel 
patient groups: one group will receive the experimental appliances and the other the conventional (control) 
appliances. At the planning phase, the statistician involved in the research team suggests to the clinicians 
that the number of patients that need to be recruited in the trial needs to be defined a priori before the trial’s 
start. This will give the trial enough statistical power to clinically identify a difference between the 
performance of the two appliances, if such a difference actually exists. 
The orthodontists involved in the research team agree that the overall treatment duration from 
insertion to removal of the fixed appliances is the most relevant endpoint for both patient and doctor, and 
should therefore be the trial’s primary outcome. Based on data from an existing trial with similar clinical 
setting to the planned trial (Yassir et al. 2018), the average expected fixed appliance treatment duration was 
found to be 29.3 months with a Standard Deviation (SD) of 9.5 months. Using their clinical subjective 
judgement, the researchers argue that the experimental appliances cost considerably more than the control 
appliances and should therefore reduce treatment duration by at least 25% (7.3 months in our case) to 
justify these increased costs. Adopting a two-sided type I error of 5% and type II error of 20% (i.e. a statistical 
power of 80%), the statistician performed a sample size calculation for a Student’s test for 2 independent 
groups and found that a total of 56 patients (28 patients in each group) would need to be recruited in the 
trial (Table 1).  
 
Table 1. Sample size calculation based for the theoretical trial’s primary outcome (overall treatment 
duration) with alpha set at 5% and beta at 20%, based on a two-sided p value from a Student’s t-test for two 
independent samples. Needed sample size is inflated by 15% (and rounded up to the next even number) to 
account for possible dropouts. 
Baseline data  Expectation  Sample needed 
Source Outcome Mean SD  
Expected 
benefit 
Expected 
mean 
 
For 
analysis 
Expecting 
dropouts 
Yassir et 
al. 2018 
Total treatment 
duration (months) 
29.30 9.50  -25% 21.98  56 66 
SD, standard deviation. 
 
After consulting with the statistician, the orthodontists set an aim to recruit 66 (33 patients in each group) 
patients in total to account for an expected 15% dropout rate. Wanting to make the most out of the existing 
material, they add in the trial’s protocol the following secondary outcomes: 
(i) patient discomfort during alignment / levelling: measured with a Likert-scale questionnaire 24 hours 
after insertion of each aligning archwire; 
(ii) gingival health: measured with Löe’s index 1 year after appliance insertion; 
(iii) duration of the alignment / levelling phase: measured in months from appliance insertion up to 
insertion of the working archwire 
(iv) duration of the working / finishing phase: measured in months from insertion of the working archwire 
to removal of the appliances. 
 
The orthodontists initiate the trial and recruit a total of 66 patients, from which 10 patients either drop out or 
are excluded from the final analysis due to missing data. At the end, data from 56 patients (28 in each group) 
are analysed statistically and indicate that no statistically significant difference (P>0.05) can be found 
between the two appliances for any of the trial’s primary or secondary outcomes. 
 
Which of the following statements are true, if any? 
(A) A sample size calculation was performed, so the present trial was probably adequately powered to 
identify a potential 25% benefit of the experimental appliance for the primary outcome of overall treatment 
duration, if such exists.  
(B) A sample size calculation was performed, so the present trial was probably adequately powered to 
identify a potential 25% benefit of the experimental appliance for any of the trial’s secondary outcomes, if 
such exists. 
(C) As no significant difference was seen between the two groups of the present trial, we can be fully 
confident that use of the experimental appliance is not associated with any benefits for any of the primary 
or secondary outcomes.  
 
Discussion 
The authors of the current trial performed an a priori sample size calculation that was based on data from a 
trial with clinical setting similar to the setting of their own trial, adopted conventional approaches for type I 
and type II errors, and made what seemed to them as reasonable clinically relevant assumptions on the 
expected treatment effect. They were prudent enough to predict that patient dropouts were to be expected 
in a follow-up of more than two years and ended up analysing at trial’s end the exact number of patients 
they had set as goal beforehand. Therefore, it is reasonable to assume that the present trial was adequately 
powered to detect a difference of 25% (7.3 months) in overall treatment duration, if such an effect exists. 
So, statement (A) is true. 
 However, this does not mean that the current trial is de factor adequately powered to investigate 
existing differences in any outcome. The authors of the current trial performed an a priori sample size 
calculation only for the trial’s primary outcome. Had the authors informed their statistician that another four 
secondary outcomes would be assessed in their trial and that the trial should be adequately powered for all 
of them, then additional sample size calculations would be needed. Based on previous trials with similar 
clinical settings (Ong et al. 2011; Kaklamanos et al. 2017; Yassir et al. 2018), under the same assumptions 
as for the primary outcome, and after accounting for dropouts the authors would need to recruit somewhere 
between 28 patients and 162 patients in total according to each outcome (Table 2). If all outcomes were to 
be adequately powered, then the authors would need to meet the highest requirement—that is, they would 
need to recruit 162 patients overall. If the assumptions made for the current sample size calculations hold 
true, then the finally analysed sample of 56 patients in the current trial is adequately powered only for the 
primary outcome of treatment duration and the secondary outcome of gingival health at 1 year. It is however, 
somewhat underpowered to identify a benefit in terms of patient discomfort (60 patients needed) and 
severely underpowered to identify a benefit in terms of alignment duration or working / finishing duration (94 
or 140 patients needed). This means that even if a substantial difference of at least 25% for any of these 
secondary outcomes actually exists, the present trial might not be able to find it or might find results that 
deviate from the truth, as seen previously (Papageorgiou, 2018). Therefore, statement (B) is (at least partly) 
false, as the trial is underpowered for three of the secondary outcomes. 
  
Table 2. Sample size calculation based for the theoretical trial’s primary outcome (overall treatment 
duration) and all secondary outcomes (discomfort, gingival health, and duration of specific treatment 
phases) with alpha set at 5% and beta at 20%, based on a two-sided p value from a Student’s t-test for two 
independent samples. Needed sample size is inflated by 15% (and rounded up to the next even number) to 
account for possible dropouts.  
Baseline data  Assumption  Sample needed 
Source Outcome Mean SD  
Assumed 
benefit 
Assumed 
mean 
 Total for 
2 groups 
Expecting 
dropouts 
Yassir et al. 
2018 
Total treatment duration 
(months) 
29.30 9.50  -25% 21.98 
 
56 66 
Ong et al. 
2011 
Discomfort at 24h (Likert 
scale) 
3.30 1.10  -25% 2.48 
 
60 70 
Kaklamanos et 
al. 2017 
Gingival index 1 year in 
treatment (Löe’s index) 
1.53 0.31  -25% 1.15 
 
24 28 
Yassir et al. 
2018 
Duration of alignment / 
levelling phase (months) 
11.8 5.0  -25% 8.85 
 
94 110 
Yassir et al. 
2018 
Duration of working / 
finishing phase (months) 
17.40 9.10  -25% 13.05 
 
140 162 
SD, standard deviation 
 
Sample size calculations in clinical trials are considered as important by funding agencies, ethics review 
boards, and journals. This is understandable, since underpowered trials might be considered unethical by 
many people, as patients might be subjected to unnecessary risks by taking part in studies that cannot 
realise their full scope or might provide misleading results. At the same time, it must be stressed out that 
sample size calculations in clinical trials might be plagued by inaccurate assumptions of baseline risk, 
erroneous calculations, a posteriori set hypothesised treatment effects, and incomplete reporting (Charles 
et al. 2009; Koletsi et al. 2014). Even if correctly executed, sample size calculation is based on statistical 
and clinical assumptions that might be questionable (Guyatt et al. 2008), while issues of feasibility usually 
play a major role when calculating the needed sample for a clinical trial. In the specific theoretical example, 
the current trial gives some evidence that the experimental appliance might not be associated with a benefit 
of the hypothesised magnitude in overall duration or gingival health. We are even less assured by provided 
evidence about the true effect of the experimental appliance as far as the patient discomfort, alignment 
phase duration, or working / finishing phase duration is concerned. Also, any single trial – regardless of how 
well powered it is – is unlikely to be able to definitively answer a clinical question and synthesis of multiple 
clinical trials with low risk of bias remains the gold standard. So, statement (C) is broadly seen false. 
Finally, it is worth of note that sample size calculations are very sensitive on the assumptions made, 
especially about the expected treatment effects, as will be illustrated in the next Statistical Corner. 
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